Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.

ABSTRACT:

Background

Maraviroc (MVC) is a candidate drug for HIV preexposure prophylaxis (PrEP).

Objective

To assess the safety and tolerability of MVC-containing PrEP over 48 weeks in U.S. women at risk for HIV infection.

Design

Phase 2 randomized, controlled, double-blinded study of 4 antiretroviral regimens used as PrEP. (ClinicalTrials.gov: NCT01505114).

Setting

12 clinical research sites of the HIV Prevention Trials Network and AIDS Clinical Trials Group.

Participants

HIV-uninfected women reporting condomless vaginal or anal intercourse with at least 1 man with HIV infection or unknown serostatus within 90 days.

Intervention

MVC only, MVC-emtricitabine (FTC), MVC-tenofovir disoproxil fumarate (TDF), and TDF-FTC (control).

Measurements

At each vi

SUBMITTER: Gulick RM 

PROVIDER: S-EPMC5667908 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature